Pfizer, BioNTech target October regulatory review for vaccine US drug maker Pfizer and its German biotechnology partner BioNTech shared positive early data from the Phase 1 study of their COVID-19 vaccine candidate, BNT162, which advanced into Phase 2/3 evaluation late last month. Based on the messenger RNA (mRNA) platform – which only mimics a SARS-CoV-2 […]
Please enter your email to receive our newsletter